about
The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukaemia geneA novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemiaEffect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialIKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trialAcute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeletonVeno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.AF6 gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer.Chromatin modification, leukaemia and implications for therapy.Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyDifferential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemiaStromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia.A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginaseIntegration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age.A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG)Microbiology, infection control and infection related outcome in pediatric patients in an oncology center in Eastern India: Experience from Tata Medical Center, Kolkata.Development of a selected reaction monitoring mass spectrometry-based assay to detect asparaginyl endopeptidase activity in biological fluidsMixed-phenotypic acute leukemia series from tertiary care center.Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia.RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia.Is there a danger in delaying radiotherapy in childhood medulloblastoma?An odyssey in search of a cure: the evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom.An audit of the activities of the paediatric oncology unit in Edinburgh, 1982-1991.SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells.Lag time for children with brain tumours.The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.Expression pattern and cellular distribution of the murine homologue of AF10.Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusionIdentification and molecular characterisation of a CALM-AF10 fusion in acute megakaryoblastic leukaemia.Screening tests for HBsAg in transfusion centres of developing countries: Authors' reply.LISA: A Clinical Information and Decision Support System for Childhood Acute Lymphoblastic Leukaemia.IntReALL HR and the benefits of adaptive design.Central venous catheter tip position and malfunction in a paediatric oncology unit.EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity.
P50
Q22010950-0512C907-FC85-4D22-B254-CB69DB91D1BAQ24316911-AD2064A0-DE1B-4BD7-891E-E5BC03244A1BQ24621523-96191D4C-C03E-4DA4-8530-4483C4770EEEQ27852750-5D585756-A8F1-4442-998A-1883DB3B6C8BQ28543517-E7955E77-52F7-4751-B7E0-F87109A2AEC7Q30843368-DF5B6646-6CF8-471B-907D-3CA33F2AEC29Q33356939-74C038B0-E0F2-426B-A85B-E1E78C2200B7Q33647130-715F512F-5F53-4457-9BDB-F52B7B13F4DDQ33746736-0260FA9A-EE3F-426D-8098-123930869C50Q34373887-5A70E63F-FFD8-4B5E-A5A6-C971997038BFQ34786248-CD76A853-E3C2-435B-83E3-227B81770BA9Q35262273-EE96D205-8FBB-40E3-A81A-36FFACAFA809Q36201257-AD840214-7D08-4A7D-AFE5-D8B38EFA17F6Q36393029-5560A0BF-C872-4935-A3D5-429395C0D6ACQ36619115-4E63EBC0-E668-4EBE-87BA-05F8784CFC3AQ37241386-C9A4EF52-70C2-48DC-8315-435F21C5A55DQ37262456-D82324D4-0879-4510-B1C4-C1DE069C1D10Q37555328-1DC67F37-7B7F-4F15-B2CB-B7AD2BA93D7DQ38468057-312F6C66-C232-46E5-92F1-6470DA1ACC7EQ38721917-A155C6D3-E4AF-420B-B07A-3647C7AACC8AQ38816612-8CDD2528-0C1A-48EE-B03D-833EB4AF54A5Q38962672-B7CEBEFE-ACCE-4B13-A841-629AF2F42335Q38999126-0224A155-1959-48DB-A88E-605FE1114D08Q39301443-0DC8E60C-A983-4051-98DB-45331D978332Q39537646-BFA63B15-ED29-4C3B-9070-5807AC0DCE91Q40771820-A7D33744-E641-404E-A5BB-D2936F5A6D01Q40791634-F6778D1F-A43B-43F7-8859-8FC8AF9F207BQ40837674-851FD507-8A33-4063-920D-F245B13B31ECQ42371491-FC8B901B-1742-4DF4-B815-1DB89B3359F5Q42377445-C8ADC98B-AE0A-4AAE-931C-72B2DC671CF7Q42544058-70AEF06D-80FB-44EC-9270-EA587FEB5BDEQ42689271-98A824CD-6FE0-4126-B913-C8489878D202Q42837969-7521D14A-416D-434E-86EC-A8B26ED99964Q43647230-94C07EAA-B23B-4D7E-8DFC-20A5D8ED8C79Q45758558-F6E83A8F-F0DB-4AB5-8785-5F68EBA46E2BQ45788164-3B8EF3AA-AAA5-4F47-97BD-CE790CA6B947Q45993119-CF517A12-595B-4FEC-A10C-0E1EEB513E70Q46071281-7EC33E64-EEA0-4CD8-A9F0-D4CFA6F88FD8Q48239769-245F7CFF-3DF3-4E19-A817-C160F2671A82Q51630975-E1B7EE64-2943-4D28-8E7D-6334C8237587
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vaskar Saha
@ast
Vaskar Saha
@en
Vaskar Saha
@es
Vaskar Saha
@nl
type
label
Vaskar Saha
@ast
Vaskar Saha
@en
Vaskar Saha
@es
Vaskar Saha
@nl
prefLabel
Vaskar Saha
@ast
Vaskar Saha
@en
Vaskar Saha
@es
Vaskar Saha
@nl
P106
P1153
7003805032
P31
P496
0000-0002-2916-9649